These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15610304)

  • 1. Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease.
    Macdonald GA; Prins JB
    J Gastroenterol Hepatol; 2004 Dec; 19(12):1335-7. PubMed ID: 15610304
    [No Abstract]   [Full Text] [Related]  

  • 2. Peroxisomes in cardiomyocytes and the peroxisome / peroxisome proliferator-activated receptor-loop.
    Colasante C; Chen J; Ahlemeyer B; Baumgart-Vogt E
    Thromb Haemost; 2015 Mar; 113(3):452-63. PubMed ID: 25608554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic steatosis and peroxisomal fatty acid beta-oxidation.
    Cherkaoui-Malki M; Surapureddi S; El-Hajj HI; Vamecq J; Andreoletti P
    Curr Drug Metab; 2012 Dec; 13(10):1412-21. PubMed ID: 22978396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
    Reddy JK; Rao MS
    Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G852-8. PubMed ID: 16603729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
    Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver lipid metabolism.
    Nguyen P; Leray V; Diez M; Serisier S; Le Bloc'h J; Siliart B; Dumon H
    J Anim Physiol Anim Nutr (Berl); 2008 Jun; 92(3):272-83. PubMed ID: 18477307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The expression of PPAR gamma in experimental fatty liver disease].
    Zhao YC; Jiang LL; Li JM; Liang BL; Li L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):437. PubMed ID: 15268815
    [No Abstract]   [Full Text] [Related]  

  • 8. [Peroxisome proliferator-activated receptor in liver diseases].
    Zhao CY; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):382-4. PubMed ID: 12837233
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of the fatty acids in ovarian functions: involvement of peroxisome proliferator-activated receptors (PPAR) and adipokines].
    Dupont J; Froment P; Ramé C; Pierre P; Coyral-Castel S; Chabrolle C
    Gynecol Obstet Fertil; 2008 Dec; 36(12):1230-8. PubMed ID: 19013096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Morizono S; Kotoh K; Yoshimoto T; Miyagi I; Enjoji M
    Int J Mol Med; 2005 Oct; 16(4):631-5. PubMed ID: 16142397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARs: fatty acid sensors controlling metabolism.
    Poulsen Ll; Siersbæk M; Mandrup S
    Semin Cell Dev Biol; 2012 Aug; 23(6):631-9. PubMed ID: 22273692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using laser scanning cytometry to measure PPAR-mediated peroxisome proliferation and beta oxidation.
    Pruimboom-Brees IM; Brees DJ; Shen AC; Keener M; Francone O; Amacher DE; Loy JK; Kerlin RL
    Toxicol Pathol; 2005; 33(1):86-91. PubMed ID: 15805059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organelle interplay in peroxisomal disorders.
    Thoms S; Grønborg S; Gärtner J
    Trends Mol Med; 2009 Jul; 15(7):293-302. PubMed ID: 19560974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 2-hydroxyacyl-CoA lyase, a thiamin pyrophosphate-dependent enzyme, in the peroxisomal metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight-chain fatty acids.
    Casteels M; Sniekers M; Fraccascia P; Mannaerts GP; Van Veldhoven PP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):876-80. PubMed ID: 17956236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of hepatic peroxisomal beta-oxidation of fatty acids by dehydroepiandrosterone (DHEA) in male F-344 rats.
    Khan SA
    Pharmazie; 2008 Dec; 63(12):915-6. PubMed ID: 19177911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G; Torres N; Tovar AR
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth and division of peroxisomes.
    Schrader M; Fahimi HD
    Int Rev Cytol; 2006; 255():237-90. PubMed ID: 17178468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 20. Dietary sesamin and docosahexaenoic and eicosapentaenoic acids synergistically increase the gene expression of enzymes involved in hepatic peroxisomal fatty acid oxidation in rats.
    Arachchige PG; Takahashi Y; Ide T
    Metabolism; 2006 Mar; 55(3):381-90. PubMed ID: 16483883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.